- Home
- ITIC vs XFOR Comparison
ITIC vs XFOR Comparison
Compare ITIC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | XFOR |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.1M | 407.5M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | ITIC | XFOR |
|---|---|---|
| Price | $213.24 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.20 |
| AVG Volume (30 Days) | 9.7K | ★ 545.9K |
| Earning Date | 05-07-2026 | 03-17-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | ★ 13.02 | N/A |
| EPS | ★ 18.57 | N/A |
| Revenue | ★ $272,755,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $108.61 |
| P/E Ratio | $11.41 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $190.20 | $0.17 |
| 52 Week High | $288.98 | $6.63 |
Technical Indicators
Market Signals| Indicator | ITIC | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 50.40 |
| Support Level | $209.71 | $3.41 |
| Resistance Level | $221.39 | $4.34 |
| Average True Range (ATR) | 5.76 | 0.33 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 16.13 | 30.50 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.